Published in Proteomics on April 01, 2010
Snapshots of protein dynamics and post-translational modifications in one experiment--beta-catenin and its functions. Mol Cell Proteomics (2011) 0.83
The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget (2016) 0.75
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells. J Cell Biol (2002) 2.62
Biologically inactive leptin and early-onset extreme obesity. N Engl J Med (2015) 2.26
Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling. Mol Cell Biol (2005) 2.24
SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res (2005) 2.15
Three separable domains regulate GTP-dependent association of H-ras with the plasma membrane. Mol Cell Biol (2004) 2.09
Cell contact-dependent acquisition of cellular and viral nonautonomously encoded small RNAs. Genes Dev (2009) 2.07
ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods (2007) 2.04
Expanding assay dynamics: a combined competitive and direct assay system for the quantification of proteins in multiplexed immunoassays. Clin Chem (2008) 1.97
Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res (2005) 1.80
Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem (2004) 1.76
A unique platform for H-Ras signaling involving clathrin-independent endocytosis. Mol Biol Cell (2007) 1.73
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res (2005) 1.73
A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol (2007) 1.71
Protein microarray technology. Trends Biotechnol (2002) 1.68
Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol (2010) 1.63
Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit. Biochem J (2003) 1.61
Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem (2002) 1.53
Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J Cell Sci (2003) 1.51
Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50
Structural and mechanistic insights into ras association domains of phospholipase C epsilon. Mol Cell (2006) 1.48
TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J Immunol (2010) 1.43
A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res (2006) 1.42
Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. Mol Biol Cell (2008) 1.39
Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology (2008) 1.37
Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res (2004) 1.36
Protein microarrays for diagnostic assays. Anal Bioanal Chem (2008) 1.35
K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res (2008) 1.29
Protein microarrays: promising tools for proteomic research. Proteomics (2003) 1.27
A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J Emerg Trauma Shock (2010) 1.25
The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol (2008) 1.25
Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine (2008) 1.25
Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res (2004) 1.24
Protein microarray technology. Drug Discov Today (2002) 1.23
Intercellular exchange of proteins: the immune cell habit of sharing. FEBS Lett (2009) 1.21
Rac2 regulation of phospholipase C-beta 2 activity and mode of membrane interactions in intact cells. J Biol Chem (2002) 1.19
A new missense mutation in the leptin gene causes mild obesity and hypogonadism without affecting T cell responsiveness. J Clin Endocrinol Metab (2010) 1.19
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol (2007) 1.19
A homolog of the human chemokine receptor CXCR1 is expressed in the mouse. Mol Immunol (2005) 1.18
The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res (2002) 1.18
Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res (2005) 1.16
Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov (2008) 1.12
FRAP beam-size analysis to measure palmitoylation-dependent membrane association dynamics and microdomain partitioning of Ras proteins. Methods (2006) 1.11
The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res (2006) 1.11
Intercellular transfer of oncogenic H-Ras at the immunological synapse. PLoS One (2007) 1.11
Protein microarrays: applications and future challenges. Curr Opin Drug Discov Devel (2005) 1.10
Galectin-3/MAC-2, Ras and PI3K activate complement receptor-3 and scavenger receptor-AI/II mediated myelin phagocytosis in microglia. Glia (2008) 1.10
p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res (2010) 1.08
Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol (2005) 1.08
Protein microarrays and multiplexed sandwich immunoassays: what beats the beads? Comb Chem High Throughput Screen (2004) 1.07
Mice deficient in the chemokine receptor CXCR4 exhibit impaired limb innervation and myogenesis. Mol Cell Neurosci (2005) 1.06
Tailoring Ras-pathway--inhibitor combinations for cancer therapy. Drug Resist Updat (2005) 1.06
Suspension microarrays for the identification of the response patterns in hyperinflammatory diseases. Med Eng Phys (2008) 1.05
Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol (2006) 1.05
Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res (2007) 1.05
Isozyme-specific stimulation of phospholipase C-gamma2 by Rac GTPases. J Biol Chem (2005) 1.05
Structural insights into formation of an active signaling complex between Rac and phospholipase C gamma 2. Mol Cell (2009) 1.05
Protein microarrays for personalized medicine. Clin Chem (2010) 1.03
Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther (2007) 1.03
Specificity and structural requirements of phospholipase C-beta stimulation by Rho GTPases versus G protein beta gamma dimers. J Biol Chem (2002) 1.03
Constitutive inositol phosphate formation in cytomegalovirus-infected human fibroblasts is due to expression of the chemokine receptor homologue pUS28. J Virol (2003) 1.01
Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cell Signal (2005) 1.00
Nonconventional trafficking of Ras associated with Ras signal organization. Traffic (2006) 1.00
Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood (2013) 0.99
Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget (2012) 0.99
Sequential multiplex analyte capturing for phosphoprotein profiling. Mol Cell Proteomics (2010) 0.99
Spatiotemporal organization of Ras signaling: rasosomes and the galectin switch. Cell Mol Neurobiol (2006) 0.99
Ras and its signals diffuse through the cell on randomly moving nanoparticles. Cancer Res (2006) 0.99
Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. Cancer Res (2011) 0.99
Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. J Invest Dermatol (2003) 0.99
Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol (2004) 0.98
Trans-SILAC: sorting out the non-cell-autonomous proteome. Nat Methods (2010) 0.98
Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther (2006) 0.95
Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer (2011) 0.95
A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today (2011) 0.94
Characterization of YopT effects on Rho GTPases in Yersinia enterocolitica-infected cells. J Biol Chem (2003) 0.94
Protein microarrays: catching the proteome. Mech Ageing Dev (2005) 0.94
Multiplex microsphere-based flow cytometric platforms for protein analysis and their application in clinical proteomics - from assays to results. Electrophoresis (2009) 0.94
rac regulates its effector phospholipase Cgamma2 through interaction with a split pleckstrin homology domain. J Biol Chem (2008) 0.94
Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res (2008) 0.93
Ras and autophagy in cancer development and therapy. Oncotarget (2014) 0.93
Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. Mol Cancer Ther (2010) 0.92
N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. Eur J Immunol (2008) 0.92
Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by up-regulating CXCR4 cell surface expression. Implications for brain inflammation. J Biol Chem (2002) 0.92
Mathematical modeling of K-Ras nanocluster formation on the plasma membrane. Biophys J (2010) 0.92
Mucus secretion and cytoskeletal modifications in cultured nasal epithelial cells exposed to wall shear stresses. Biophys J (2008) 0.92
Constitutive serum response factor activation by the viral chemokine receptor homologue pUS28 is differentially regulated by Galpha(q/11) and Galpha(16). Cell Signal (2008) 0.91
Microsphere-based co-immunoprecipitation in multiplex. Anal Biochem (2009) 0.91
Targeting peptide termini, a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification. Mol Cell Proteomics (2010) 0.90
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. J Med Chem (2009) 0.90
Protein microarray technology. Front Biosci (2002) 0.90
A dual array-based approach to assess the abundance and posttranslational modification state of signaling proteins. Sci Signal (2012) 0.90
A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res (2008) 0.89
Differences in CXCR4-mediated signaling in B cells. Immunobiology (2006) 0.89
Proteome wide screening using peptide affinity capture. Proteomics (2009) 0.89